Cargando…

Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?

Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hrdý, Jiří, Súkeníková, Lenka, Petrásková, Petra, Novotná, Olga, Kahoun, David, Petříček, Miroslav, Chroňáková, Alica, Petříčková, Kateřina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284804/
https://www.ncbi.nlm.nih.gov/pubmed/32344935
http://dx.doi.org/10.3390/microorganisms8050621
_version_ 1783544553736765440
author Hrdý, Jiří
Súkeníková, Lenka
Petrásková, Petra
Novotná, Olga
Kahoun, David
Petříček, Miroslav
Chroňáková, Alica
Petříčková, Kateřina
author_facet Hrdý, Jiří
Súkeníková, Lenka
Petrásková, Petra
Novotná, Olga
Kahoun, David
Petříček, Miroslav
Chroňáková, Alica
Petříčková, Kateřina
author_sort Hrdý, Jiří
collection PubMed
description Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators—tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes—manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25–5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides.
format Online
Article
Text
id pubmed-7284804
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72848042020-06-15 Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs? Hrdý, Jiří Súkeníková, Lenka Petrásková, Petra Novotná, Olga Kahoun, David Petříček, Miroslav Chroňáková, Alica Petříčková, Kateřina Microorganisms Article Current treatment of chronic diseases includes, among others, application of cytokines, monoclonal antibodies, cellular therapies, and immunostimulants. As all the underlying mechanisms of a particular diseases are not always fully clarified, treatment can be inefficient and associated with various, sometimes serious, side effects. Small secondary metabolites produced by various microbes represent an attractive alternative as future anti-inflammatory drug leads. Compared to current drugs, they are cheaper, can often be administered orally, but still can keep a high target-specificity. Some compounds produced by actinomycetes or fungi have already been used as immunomodulators—tacrolimus, sirolimus, and cyclosporine. This work documents strong anti-inflammatory features of another secondary metabolite of streptomycetes—manumycin-type polyketides. We compared the effect of four related compounds: manumycin A, manumycin B, asukamycin, and colabomycin E on activation and survival of human monocyte/macrophage cell line THP-1. The anti-cancer effect of manucycine A has been demonstrated; the immunomodulatory capacities of manumycin A are obvious when using micromolar concentrations. The application of all four compounds in 0.25–5 μM concentrations leads to efficient, concentration-dependent inhibition of IL-1β and TNF expression in THP-1 upon LPS stimulation, while the three latter compounds show a significantly lower pro-apoptotic effect than manumycin A. We have demonstrated the anti-inflammatory capacity of selected manumycin-type polyketides. MDPI 2020-04-25 /pmc/articles/PMC7284804/ /pubmed/32344935 http://dx.doi.org/10.3390/microorganisms8050621 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hrdý, Jiří
Súkeníková, Lenka
Petrásková, Petra
Novotná, Olga
Kahoun, David
Petříček, Miroslav
Chroňáková, Alica
Petříčková, Kateřina
Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title_full Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title_fullStr Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title_full_unstemmed Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title_short Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes—A Potential Alternative to Current Anti-Inflammatory Drugs?
title_sort inhibition of pro-inflammatory cytokines by metabolites of streptomycetes—a potential alternative to current anti-inflammatory drugs?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284804/
https://www.ncbi.nlm.nih.gov/pubmed/32344935
http://dx.doi.org/10.3390/microorganisms8050621
work_keys_str_mv AT hrdyjiri inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT sukenikovalenka inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT petraskovapetra inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT novotnaolga inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT kahoundavid inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT petricekmiroslav inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT chronakovaalica inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs
AT petrickovakaterina inhibitionofproinflammatorycytokinesbymetabolitesofstreptomycetesapotentialalternativetocurrentantiinflammatorydrugs